HSP110 Inhibition in Primary Effusion Lymphoma Cells: One Molecule, Many Pro-Survival Targets
暂无分享,去创建一个
G. D’Orazi | M. Cirone | A. Arena | R. Gonnella | M. S. Gilardini Montani | R. Santarelli | Rossella Benedetti | Roberta Zarrella | Michele Di Crosta
[1] R. Ramaswami,et al. Clinical management of Kaposi sarcoma herpesvirus-associated diseases: an update on disease manifestations and treatment strategies , 2023, Expert review of anti-infective therapy.
[2] K. Öllinger,et al. Real-Time Monitoring of Lysosomal Membrane Permeabilization Using Acridine Orange , 2023, Methods and protocols.
[3] M. Cirone,et al. HSPs/STAT3 Interplay Sustains DDR and Promotes Cytokine Release by Primary Effusion Lymphoma Cells , 2023, International journal of molecular sciences.
[4] M. Cirone,et al. JQ-1/Bortezomib combination strongly impairs MM and PEL survival by inhibiting c-Myc and mTOR despite the activation of pro-survival mechanisms. , 2023, Experimental hematology.
[5] A. C. Gasparovic,et al. DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities , 2022, International journal of molecular sciences.
[6] Ying Luo,et al. HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review) , 2022, Oncology reports.
[7] M. Tainsky,et al. DNA Repair Mechanisms, Protein Interactions and Therapeutic Targeting of the MRN Complex , 2022, Cancers.
[8] Qingsong Liu,et al. Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities , 2022, MedComm.
[9] M. Cirone,et al. Targeting c-Myc Unbalances UPR towards Cell Death and Impairs DDR in Lymphoma and Multiple Myeloma Cells , 2022, Biomedicines.
[10] Yao Xiao,et al. Recent advances in DDR (DNA damage response) inhibitors for cancer therapy. , 2022, European journal of medicinal chemistry.
[11] M. Cirone,et al. DNA damage triggers an interplay between wtp53 and c-Myc affecting lymphoma cell proliferation and KSHV replication. , 2021, Biochimica et biophysica acta. Molecular cell research.
[12] Shuxian Yang,et al. Recent advances in heat shock proteins in cancer diagnosis, prognosis, metabolism and treatment. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[13] G. Chakafana,et al. The Role of Non-Canonical Hsp70s (Hsp110/Grp170) in Cancer , 2020, Cells.
[14] C. Garrido,et al. Chaperoning STAT3/5 by Heat Shock Proteins: Interest of Their Targeting in Cancer Therapy , 2019, Cancers.
[15] G. D’Orazi,et al. Mutant p53, Stabilized by Its Interplay with HSP90, Activates a Positive Feed-Back Loop Between NRF2 and p62 that Induces Chemo-Resistance to Apigenin in Pancreatic Cancer Cells , 2019, Cancers.
[16] O. Demidov,et al. HSP110 translocates to the nucleus upon genotoxic chemotherapy and promotes DNA repair in colorectal cancer cells , 2018, Oncogene.
[17] Songbo Xie,et al. Therapeutic targeting of cellular stress responses in cancer , 2018, Thoracic cancer.
[18] F. Jardin,et al. HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization. , 2018, Blood.
[19] Mayra L. Sottile,et al. Heat shock proteins and DNA repair mechanisms: an updated overview , 2018, Cell Stress and Chaperones.
[20] O. Demidov,et al. HSP110 promotes colorectal cancer growth through STAT3 activation , 2017, Oncogene.
[21] N. Marchenko,et al. Mutant p53 – Heat Shock Response Oncogenic Cooperation: A New Mechanism of Cancer Cell Survival , 2015, Front. Endocrinol..
[22] C. Tripodo,et al. HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma. , 2015, Blood.
[23] J. Briones. Heat-shock proteins: a c-Myc lymphoma target? , 2015, Blood.
[24] L. Frati,et al. HSP70 inhibition by 2-phenylethynesulfonamide induces lysosomal cathepsin D release and immunogenic cell death in primary effusion lymphoma , 2013, Cell Death and Disease.
[25] Bhairavi Tolani,et al. Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors , 2013, Oncogene.
[26] Abena B. Redwood,et al. A new pathway that regulates 53BP1 stability implicates Cathepsin L and vitamin D in DNA repair , 2011, The EMBO journal.
[27] Arnaud M. Vigneron,et al. The STAT3 Transcription Factor Is a Target for the Myc and Riboblastoma Proteins on the Cdc25A Promoter* , 2005, Journal of Biological Chemistry.
[28] G. Feldman,et al. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. , 2003, Blood.
[29] Michael M. Murphy,et al. ATM Phosphorylates Histone H2AX in Response to DNA Double-strand Breaks* , 2001, The Journal of Biological Chemistry.
[30] T. Yeatman,et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.